BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31259881)

  • 1. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review.
    Demlová R; Turjap M; Peš O; Kostolanská K; Juřica J
    Ther Drug Monit; 2020 Feb; 42(1):20-32. PubMed ID: 31259881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
    Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
    J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
    Westerdijk K; Krens SD; van der Graaf WTA; Mulder SF; van Herpen CML; Smilde T; van Erp NP; Desar IME
    Br J Clin Pharmacol; 2021 Feb; 87(2):326-335. PubMed ID: 32358810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
    Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
    Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
    Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
    Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA; Heng DYC; Macfarlane RJ; Venner PM; Kapoor A; Hansen AR; Eigl BJ; Czaykowski P; Boyd B; Wang L; Basappa NS
    Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
    Verschuur AC; Bajčiová V; Mascarenhas L; Khosravan R; Lin X; Ingrosso A; Janeway KA
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):41-50. PubMed ID: 31006038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
    Goulooze SC; Galettis P; Boddy AV; Martin JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):209-16. PubMed ID: 27295055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
    Yu Y; DuBois SG; Wetmore C; Khosravan R
    AAPS J; 2020 Jan; 22(2):31. PubMed ID: 31975150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
    Gandhi KA; Joshi A; Mehta P; Gurjar M; Rane P; Sharma J; Patil A; Nookala M; Noronha V; Prabhash K; Gota V
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):751-759. PubMed ID: 35441269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
    Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
    Wang E; DuBois SG; Wetmore C; Verschuur AC; Khosravan R
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):343-352. PubMed ID: 33852135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
    Khosravan R; Motzer RJ; Fumagalli E; Rini BI
    Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
    Mansueto G; Longo F
    Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
    [No Abstract]   [Full Text] [Related]  

  • 19. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in solid tumors.
    Gan HK; Seruga B; Knox JJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.